Expert views
Recombinant factor VIII in haemophilia A: Real-world evidence
Real-world studies may bridge the knowledge gap between the performance of a therapy in the highly controlled environment of a clinical trial and its use in clinical practice. In studies of therapies for haemophilia A this is particularly useful for analysing pharmacokinetics, dosing and consumption and efficacy of treatment.
In this video, Martin Olivieri highlights recent real-world studies of factor VIII replacement products and how those outcomes compare with clinical trial results.